Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 5
Submit an article Journal homepage
351
Views
0
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1

Sonja BurgstallerDepartment of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria; Correspondence[email protected]
View further author information
,
Reinhard StauderDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria; View further author information
,
Thomas KuehrDepartment of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria; View further author information
,
Alois LangDepartment of Internal Medicine, Landeskrankenhaus Feldkirch, Feldkirch, Austria; View further author information
,
Sigrid Machherndl-SpandlDepartment of Internal Medicine I, Krankenhaus der Elisabethinen, Linz, Austria; View further author information
,
Beate MayrbaeurlDepartment of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria; View further author information
,
Thomas NoesslingerDepartment of Hematology and OncologyIII, Hanusch Hospital, Vienna, Austria; ;Ludwig-Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria; View further author information
,
Andreas PetzerDepartment of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern, Linz.Austria; View further author information
,
Peter ValentLudwig-Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria; ;Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; View further author information
,
Richard Greil3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Salzburg, AustriaView further author information
&
Josef ThalerDepartment of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria; View further author information
 show all
Pages 1121-1126 | Received 22 Jun 2017, Accepted 12 Aug 2017, Published online: 30 Aug 2017

References

  • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–941.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classfication fo myeloid neoplasms an acute leukemia. Blood. 2016;127:2391–2405.
  • Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.
  • Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. Blood. 1996;88:2480–2487.
  • Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17:908–915.
  • Park S, Labopin M, Yakoub-Agha I, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013;90:355–364.
  • Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117:2690–2696.
  • Fianchi L, Criscuolo M, Breccia M, et al. High rate of remissions in chronic myelomonoctic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma. 2013;54:658–661.
  • Thorpe M, Montalvao A, Pierdomenico F, et al. Treatment of chronic myelomonocytic leukemia with 5-Azacytidine; a case series and literature review. Leuk Res. 2012; 36:1071–1073.
  • Wong E, Seymour JF, Kenealy M, et al. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma. 2013;54:878–880.
  • Adès L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013;37:609–613.
  • Pleyer L, Germing U, Sperr WR, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38:475–483.
  • Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. [2017 July 7]. DOI:10.1038/leu.2017.186
  • Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118:3824–3831.
  • List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
  • Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93.
  • Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708–720.
  • Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674.
  • Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–1361.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
  • Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients With myelodysplastic syndrome: studies 8421, 8921 and 9221 by the cancer and leukemia group B. J Clin Oncol. 2006;24:3895–3903.
  • Padron E, Dezern A, Andrade-Campos M, , et al. A multi-institutional phase 1 trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res. 2016;22:3746–3754.
  • Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125:1857–1865.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.